A prospective comparison study of subcutaneous and intramuscular testosterone injections in transgender male adolescents

被引:1
|
作者
Baines, Hayley K. [1 ]
Connelly, Kara J. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Dept Pediat, Div Pediat Endocrinol, 707 SW Gaines St, Portland, OR 97239 USA
来源
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM | 2023年 / 36卷 / 11期
关键词
testosterone; gender affirming care; transgender health; gender diverse youth; MENTAL-HEALTH; GENDER; THERAPY; PHARMACOKINETICS; ACCEPTABILITY; ADULTS; YOUTH; CARE;
D O I
10.1515/jpem-2023-0237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This prospective study compares testosterone injection type and effects on biochemical changes, clinical effects, and quality of life amongst transgender and gender diverse (TGD) adolescents assigned female at birth (AFAB) over the first 6 months of subcutaneous (SQ) vs. intramuscular (IM) testosterone injections as part of their gender affirming care.Methods Subjects were testosterone-naive transgender adolescents, AFAB, ages 14-18 years old. Subjects were either randomized to injection type or selected a preferred injection type. At enrollment, subjects completed baseline labs and PedsQL (TM) quality of life questionnaire. At 3 month and 6 month follow up, subjects completed peak and trough testosterone levels, PedsQL (TM), masculinizing effects, and medication experience questionnaires.Results Twenty-six subjects participated with a median age 15.5 years. By 6-month follow up, trough testosterone levels were comparable between the two groups. Peak testosterone levels were higher in the IM group at 3-month follow up. Mild adverse effects were rare (12 %, all in SQ subjects) and limited to skin reaction only. Self-reported masculinization effects and quality of life were not statistically different between injection groups. A total of 92 % of participants was self-injecting by 3-month follow up.Conclusions In this prospective study, clinical and biochemical effects are similar between SQ and IM testosterone injections for transgender adolescents. Subjects expressed preference for both injection types. Both SQ and IM injection modalities are safe and effective for TGD youth initiating testosterone and both options should be offered to patients.
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 50 条
  • [21] Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism
    Minnemann, T.
    Schubert, M.
    Freude, S.
    Huebler, D.
    Gouni-Berthold, I.
    Schumann, C.
    Christoph, A.
    Oettel, M.
    Ernst, M.
    Mellinger, U.
    Krone, W.
    Jockenhoevel, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (08) : 718 - 723
  • [22] Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: A prospective, observational study
    Glaser, Rebecca L.
    Dimitrakakis, Constantine
    MATURITAS, 2013, 76 (04) : 342 - 349
  • [23] Testosterone Treatment and MMPI-2 Improvement in Transgender Men: A Prospective Controlled Study
    Keo-Meier, Colton L.
    Herman, Levi I.
    Reisner, Sari L.
    Pardo, Seth T.
    Sharp, Carla
    Babcock, Julia C.
    JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2015, 83 (01) : 143 - 156
  • [24] The Impact of Testosterone Therapy on the Vaginal Microbiota of Transgender Men and Nonbinary People: A Prospective Study
    Van Gerwen, Olivia T.
    Aaron, Kristal J.
    Kay, Emma Sophia
    Siwakoti, Krishmita
    Pontius, Angela
    Richter, Saralyn
    Sherman, Z. Alex
    Graves, Keonte J.
    Tamhane, Ashutosh
    Elnaggar, Jacob H.
    Luo, Meng
    Toh, Evelyn
    Nelson, David E.
    Van Wagoner, Nicholas J.
    Taylor, Christopher M.
    Muzny, Christina A.
    JOURNAL OF INFECTIOUS DISEASES, 2025,
  • [25] Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals
    Jacobeit, J. W.
    Gooren, L. J.
    Schulte, H. M.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (05) : 795 - 798
  • [26] A study on serum levels of testosterone and prolactin hormones in male epileptic adolescents
    Rabie, Mohamed Osman
    El-din, El-Sayed Ali Tag
    Rashed, Khaled H.
    Bahnasy, Wafik S.
    El-Serogy, Hesham A.
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2016, 53 (02): : 79 - 83
  • [27] Comparison of the Pharmacokinetics of Ketorolac Tromethamine After Continuous Subcutaneous Infusion and Repeat Intramuscular Bolus Injections in Healthy Adult Subjects
    Burdick, Michael
    Mamelok, Richard
    Hurliman, Michele
    Dupuis, Marieve
    Xie, Yuli
    Grenier, Julie
    Sheldon, Curtis
    Gartner, Michael
    Noymer, Peter
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (04): : 343 - 349
  • [28] Safety and efficacy of intramuscular injections of 1000 mg testosterone undecanoate: A prospective multicenter study in hypogonadal men under conditions resembling real-life situations
    Behre, H. M.
    Elliesen, J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 108 - 108
  • [29] INITIAL EVALUATION OF SAFETY AND EFFICACY OF ADMINISTRATION OF ESTRADIOL (E2) BY SUBCUTANEOUS (SC) INJECTIONS TO MALE-TO-FEMALE (MTF) TRANSGENDER
    LaBudde, Jennifer A.
    Craig, Wendy Y.
    Spratt, Daniel I.
    FERTILITY AND STERILITY, 2020, 114 (03) : E91 - E91
  • [30] Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study
    Perl, Liat
    Segev-Becker, Anat
    Israeli, Galit
    Elkon-Tamir, Erella
    Oren, Asaf
    LGBT HEALTH, 2020, 7 (06) : 340 - 344